BioMAP® Combo ELECT Service

Version:: 020617
File Name/Number:: 20017
Year:: 2017

With potential combination partners to choose from growing exponentially, there is a major need for guidance in designing rational combinations including which agents and what concentrations to use for appropriate in vivo exposures. Target-agnostic based approaches such as in vitro phenotypic assays provide a compelling strategy to compare combinations with the corresponding individual agents in a head-to-head screening format. Testing the efficacy and safety of drugs versus combinations prior to clinical administration can improve the availability and feasibility of such a therapeutic approach.